Carmot Therapeutics announced its acquisition by Roche has been completed. Recall, Carmot and Roche entered into a definitive merger agreement for Roche to acquire Carmot for $2.7B upfront with the potential for $400M in milestone payments (previous FENIX insight). Below, FENIX provides brief highlights and insights on the acquisition.
Five cardiometabolic-related news items have been observed from Lilly, Biocorp, and Novo Nordisk. Below, FENIX provides highlights and insights for the respective news items.
Two cardiometabolic-related news items have been observed: Abbott hosted its Q4 ’23 earnings call (press release; infographic); and Sciwind announced interim Ph1 data for its oral GLP-1RA (view press release). Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: Novo Nordisk entered a collaboration and licensing agreement with EraCal for its oral, small molecule asset for obesity (view press release); Scholar Rock announced IND clearance to initiate Ph2 PoC trial with its myostatin inhibitor for obesity (view press release); and J&J hosted its Q4 ’23 earnings call (press release; slides). Below, FENIX provides highlights and insights for the respective news items.
Two cardiometabolic-related news items have been observed: the CHMP agenda (view here) for this month’s meeting (January 22-25) has been released and includes Novo’s SELECT; and Akero initiated the second Ph3 study evaluating EFX in participants with non-cirrhotic MASH and F2 or F3 fibrosis (SYNCHRONY Histology; view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.
Two cardiometabolic-related news items have been observed: Dexcom announced its first manufacturing facility in the EU for CGM sensors (view press release); and FDA has reportedly uncovered new manufacturing problems at a Lilly plant (view article). Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: Lilly has reportedly planned additional Mounjaro launches in 2024 once it receives EU approval for its pen injector (view article); FDA posted a Class 2 device recall for the Libre 3 Android App which was resolved in February 2023 (view recall); and Novo initiated a Ph1 cagrisema study (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Novo, Amgen, Dexcom, and Boehringer Ingelheim. Below, FENIX provides highlights and insights for the respective news items.
On the fourth and last day of JPM 2024, FENIX has provided coverage of presentations by other CVRM companies, including Madrigal, Lexicon, MannKind, and Akebia. Xeris also presented at JPM 2024 but had no meaningful discussion relating to its CVRM portfolio. Separately, one CVRM-related news item has been observed: Novartis has reportedly decided to no longer pursue a Cytokinetics acquisition (view article).
On the third day of JPM 2024, FENIX has provided coverage of presentations by other CVRM companies, including Terns, Esperion, Ionis, Amarin, Embecta, and Viatris. Tomorrow is the final day of the JPM 2024 conference with presentations from Lexicon, Mannkind, and Xeris.